ArticleCroatian medical journal2025
Risk factors associated with adverse cardiovascular events during orthotopic liver transplantation and the early post-transplant period.
Article in Croatian medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Refining anesthesia practice - regional techniques, risk stratification, and evidence-based analgesia.Croatian medical journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo evaluate the incidence of severe adverse cardiovascular events during orthotopic liver transplantation and the early post-transplant period, and to determine the factors associated with these events.
methodsWe retrospectively reviewed the medical records of 291 patients who underwent orthotopic liver transplantation at University Center Merkur, Zagreb, Croatia, from 2013 to 2015. Data on corresponding donor characteristics were sourced from the Eurotransplant database. Severe adverse cardiovascular events were defined as myocardial infarction, malignant arrhythmia, pulmonary embolism, cardiac failure, cardiac arrest, and death.
resultsThe incidence of severe adverse events was 8.9%. Univariate analysis demonstrated a positive predictive value linking severe adverse cardiovascular events with metabolic liver disease, an elevated model for end-stage liver disease, an international normalized ratio, and the preoperative administration of vasopressors. Multivariate analysis identified significant predictors of adverse events: liver metabolic diseases (odds ratio [OR] 4.88; 95% confidence interval [CI] 1.48-16.09; P=0.009), donor arterial hypertension (OR 2.68; 95% CI 1.01-7.18; P=0.049), prolonged cold ischemia duration (OR 1.22; 95% CI 1.01-1.49; P=0.044), and increased recipient age (OR 1.09; 95% CI 1.03-1.16; P=0.005).
conclusionThe occurrence of severe adverse cardiovascular events is markedly greater than previously documented. We propose the use of a scoring system including known risk variables to identify patients at risk of adverse cardiovascular events, hence improving surveillance for an early intervention.
Indexed as
Identifiers
40635340PMC12246966What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.